Voting results of the Fiscal 2025 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 17, 2025 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders, in Amsterdam-Schipol, chaired by Didier Michaud-Daniel, Executive Chair of Pluxee’s Board of Directors. All resolutions on the agenda were approved by the shareholders. This included the adoption of the financial statements for the fiscal year which ended on August 31, 2025 (“Fiscal 2025”), and of the dividend distribution ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven safety and robotics solutions company, today announced that it has established a non-binding supplier framework to support the deployment of its solutions for a government agency in Japan. The framework outlines a collaborative path to introduce AMC’s quadruped robotics platform and expand its capabilities for the Japanese market. This includes joint work on AI-powered security ...

公司核心业务与平台技术 - Acrivon Therapeutics是一家临床阶段生物技术公司，专注于利用其专有的生成性磷酸化蛋白质组学AP3平台发现和开发精准药物 [1][2] - AP3平台能够以无偏见的方式在完整细胞内解释和量化化合物特异性、药物调控的通路活性水平，生成TB级别的专有数据，并提供快速、可操作的见解 [2] - AP3平台包含一套不断增长的强大内部开发工具，如AP3数据门户、AP3激酶底物关系预测器和AP3相互作用组，这些工具将多模态数据转换为结构化数据以进行生成式AI分析 [2] - 该平台使公司能够超越传统药物发现以及当前基于AI的靶点中心药物发现的局限，通过细胞内蛋白质网络分析快速设计具有理想通路效应的差异化化合物，并推进这些药物进入临床进行简化开发 [2] 核心在研产品管线进展 - 公司主要项目ACR-368（又称prexasertib）是一种靶向CHK1和CHK2的选择性小分子抑制剂，目前正在一项可能成为注册依据的2b期试验中用于子宫内膜癌治疗 [3] - ACR-368作为单药疗法已获得美国FDA的快速通道资格，该资格基于OncoSignature预测的子宫内膜癌患者敏感性 [3] - 用于识别可能从ACR-368治疗中获益的子宫内膜癌患者的ACR-368 OncoSignature检测已获得FDA的突破性医疗器械认定 [3] - 公司第二款临床阶段资产ACR-2316是一种新型、强效、选择性的WEE1/PKMYT1抑制剂，临床前研究表明其通过强烈激活CDK1、CDK2以及PLK1来驱动促凋亡细胞死亡，显示出优于基准抑制剂的单药活性 [4] - ACR-2316的1期试验正在推进，前三个剂量递增队列的入组已完成 [4] - 在剂量水平1和2，使用公司的临床质谱AP3分析观察到了药物靶点结合，基于血浆药代动力学分析有证据显示大致剂量比例关系，在剂量水平3观察到初步临床活性及肿瘤缩小 [4] - 公司还在推进一个针对未公开细胞周期调控靶点的临床前项目 [4] 近期数据发布计划 - 公司将于2026年1月通过电话会议和网络直播提供ACR-368和ACR-2316的临床数据及其他更新 [1] - 计划更新的内容包括：来自正在进行的有注册意图的2b期研究的ACR-368最新中期临床数据、关于最近启动的独立于肿瘤活检的额外2b期研究组的更新、以及计划中的确证性3期试验 [6] - 计划更新的内容包括：来自正在进行中的ACR-2316（一款潜在同类首创和同类最佳的WEE1/PKMYT1抑制剂）1期研究的初步临床数据，包括安全性数据、给药方案以及在AP3优先排序的实体瘤类型中的早期临床活性 [6] - 计划更新的内容包括：为Acrivon的AP3驱动的细胞周期项目提名新的临床前开发候选药物，包括靶点披露 [6]

SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions, today announced the filing of a shelf registration statement on Form F-3 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement is intended to provide the Company with the flexibility to offer and sell, from time to time, up to an aggregate amount of US$100,000,00 ...

Positive progress in operations at Renergen’s Virginia Gas Project with a production update expected at the end of January 2026WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that all required regulatory approvals and clearances have been obtained for ASP Isotopes’ proposed offer t ...

FREUDENSTADT, Germany, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SCHMID Group N.V. (NASDAQ: SHMD) (the "Company"), a global leader in providing solutions to the high-tech electronics, photovoltaics, glass, and energy systems industries, announced today that it signed an agreement for a secured two-tranche term loan facility for up to €10,000,000 with Black Forest Special Situations I, a vehicle established in the Cayman Islands (the "Lender"). The term loan facility includes an optional equity conversion right of t ...

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share. The gross proceeds to Kyverna from the offering, before deducting underwriting discounts and commissions and offering expenses payabl ...

ATHENS, Greece, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, provides a commercial update on earnings and vessel employment. Vessel Employment Updates In December 2025, we extended the time charter of the M/V Alfa with an international commodity trading conglomerate for an indefinite period, expiring upon three month ...

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinica ...

Enrollment completion follows a previously announced positive independent Data Safety Monitoring Board (DSMB) safety review, which confirmed that CELZ-201 demonstrated a favorable safety profile with no significant adverse events and supported continued advancement of the trial. With enrollment now complete, CELZ has reached a critical execution milestone, transitioning the ADAPT program into its next phase focused on follow-up, and data analysis. Company leadership, investigators, and clinical partners exp ...